{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:39:42Z","timestamp":1791099582913,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.jdermsci.2012.04.002","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T15:19:17Z","timestamp":1334243957000},"page":"190-196","source":"Crossref","is-referenced-by-count":82,"title":["Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis"],"prefix":"10.1016","volume":"66","author":[{"given":"Wen-Hung","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuen-Iu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2012.04.002_bib0005","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0010","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","article-title":"The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification","volume":"102","author":"Roujeau","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0015","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0020","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0030","series-title":"Drug hypersensitivity","first-page":"18","article-title":"Epidemiology and causes of severe cutaneous adverse reactions to drugs","author":"Mockenhaupt","year":"2007"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/01.all.0000173785.81024.33","article-title":"Epidemiology of hypersensitivity drug reactions","volume":"5","author":"Gomes","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.BCR.0000150215.78220.79","article-title":"Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center","volume":"26","author":"Haber","year":"2005","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0045","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ophtha.2006.10.029","article-title":"New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome","volume":"114","author":"Sotozono","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0055","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998\u20132008","author":"Zajicek","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0060","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/pds.2276","article-title":"Spontaneous adverse event reports of Stevens-Johnson syndrome\/toxic epidermal necrolysis: detecting associations with medications","volume":"21","author":"Papay","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0065","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1212\/WNL.0b013e31823b478c","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs in Asians","volume":"77","author":"Yang","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0070","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02113442","article-title":"Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection","volume":"14","author":"Fournier","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0075","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0310057X0703500317","article-title":"Mycoplasma pneumoniae associated with Stevens Johnson syndrome","volume":"35","author":"Mulvey","year":"2007","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11532540-000000000-00000","article-title":"New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited","volume":"33","author":"Paquet","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0085","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0090","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.burns.2009.06.213","article-title":"Toxic epidermal necrolysis (Lyell's disease)","volume":"36","author":"Lissia","year":"2010","journal-title":"Burns"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0095","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1365-4632.2007.03277.x","article-title":"Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"46","author":"Fromowitz","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0105","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Borchers","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0110","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0115","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0120","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0125","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0135","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","article-title":"HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"51","author":"Kaniwa","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0140","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0145","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0150","unstructured":"Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, et al. HLA-A*3101 is more strongly associated with carbamazepine-induced drug reaction with eosinophilia and systemic symptoms than with carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis [abstract PV130]. Presented at: 5th Drug Hypersensitivity Meeting (Programme & Abstract Book DHM5 2012: P34-35); April 11\u201314 2012."},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0155","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2217\/pgs.10.54","article-title":"HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Kim","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0160","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0165","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.seizure.2011.02.003","article-title":"Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland","volume":"20","author":"Wang","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0170","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00228-011-1009-4","article-title":"Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients","volume":"67","author":"Zhang","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0175","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population","volume":"50","author":"Chang","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome\u2026: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0190","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians","volume":"75","author":"Mehta","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0195","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans","volume":"97","author":"Kim","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0200","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14740330903427969","article-title":"Genetic predisposition of life-threatening antiepileptic-induced skin reactions","volume":"9","author":"Chung","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0205","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0210","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","article-title":"HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions","volume":"51","author":"Ikeda","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0215","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jaci.2010.11.048","article-title":"Immune pathomechanism of drug hypersensitivity reactions","volume":"127","author":"Pichler","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0220","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/eji.1830270602","article-title":"Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy","volume":"27","author":"Padovan","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0225","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0230","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1124\/mol.63.3.732","article-title":"Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones","volume":"63","author":"Naisbitt","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0235","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI3544","article-title":"HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes","volume":"102","author":"Zanni","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0375","doi-asserted-by":"crossref","unstructured":"Wei CY, Chung WH, Huang HW, Chen YT, Hung SI. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012, in press.","DOI":"10.1016\/j.jaci.2011.12.990"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0245","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","article-title":"Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome","volume":"128","author":"Ko","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0250","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2007.06.017","article-title":"HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome","volume":"120","author":"Yang","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0255","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archderm.140.2.242","article-title":"Kinetics and specificity of fas ligand induction in toxic epidermal necrolysis","volume":"140","author":"Chang","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0260","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0265","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-79414-8_1","article-title":"Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity","volume":"198","author":"Lowin","year":"1995","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0275","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0280","doi-asserted-by":"crossref","first-page":"514","DOI":"10.7326\/0003-4819-151-7-200910060-00016","article-title":"Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome","volume":"151","author":"Abe","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0285","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1189\/jlb.0409222","article-title":"Induction of granulysin in CD8+ T cells by IL-21 and IL-15 is suppressed by human immunodeficiency virus-1","volume":"86","author":"Hogg","year":"2009","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0290","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00000372-200010000-00005","article-title":"Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis","volume":"22","author":"Paquet","year":"2000","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0295","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mjd.2002.120473","article-title":"Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis","volume":"47","author":"Correia","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0300","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0305","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2004.04.034","article-title":"Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions","volume":"114","author":"Tapia","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0310","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","article-title":"Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"155","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0315","first-page":"555","article-title":"The use of intravenous high-dose immunoglobulins (IGIV) in a case of Stevens-Johnson syndrome","volume":"14","author":"Amato","year":"1992","journal-title":"Pediatr Med Chir"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0320","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0325","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2165\/00003495-200565150-00002","article-title":"Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date","volume":"65","author":"Faye","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0330","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0335","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2500\/108854192778878926","article-title":"Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS","volume":"13","author":"Patterson","year":"1992","journal-title":"Allergy Proc"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0340","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0345","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0350","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1006\/bbrc.1997.6658","article-title":"Cyclosporin A-sensitive calcium signaling represses NFkappaB activation in human bronchial epithelial cells and enhances NFkappaB activation in Jurkat T-cells","volume":"234","author":"Aoki","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0355","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0360","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s004150050360","article-title":"Cyclosporine neurotoxicity: a review","volume":"246","author":"Gijtenbeek","year":"1999","journal-title":"J Neurol"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0365","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdermsci.2012.04.002_bib0370","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092318111200134X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092318111200134X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T05:37:50Z","timestamp":1561613870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092318111200134X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S092318111200134X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2012.04.002","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}